EyePoint Pharmaceuticals, Inc.
NASDAQ Global MarketTotal Valuation
EyePoint Pharmaceuticals, Inc. carries a market capitalization of 1.03B, placing it among publicly traded companies globally. Its enterprise value stands at 793.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.03B |
| Enterprise Value | 793.84M |
Share Statistics
EyePoint Pharmaceuticals, Inc. currently has 83.45M shares outstanding.
| Shares Outstanding | 83.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 130.81, and the price-to-book ratio stands at -0.84.
| PE Ratio | N/A |
| PS Ratio | 130.81 |
| PB Ratio | -0.84 |
| P/TBV Ratio | 4.32 |
| P/FCF Ratio | -3.78 |
| P/OCF Ratio | -3.72 |
Enterprise Valuation
| EV / Sales | 104.25 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
EyePoint Pharmaceuticals, Inc. maintains a current ratio of 6.66, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.66 |
| Quick Ratio | 5.97 |
| Debt / Equity | 8.78 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -83.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.06 |
Taxes
| Income Tax | 229,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
EyePoint Pharmaceuticals, Inc.'s stock has gained approximately 51.97044% over the past 52 weeks. The 50-day moving average sits at 13.42, while the 200-day moving average is 14.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | 51.97044% |
| 50-Day Moving Average | 13.42 |
| 200-Day Moving Average | 14.05 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, EyePoint Pharmaceuticals, Inc. generated 7.62M in revenue and converted that into -271.60M in net income, yielding earnings per share of -3.51. EBITDA reached -279.37M, while operating income came in at -281.82M.
| Revenue | 7.62M |
| Gross Profit | 5.83M |
| Operating Income | -281.82M |
| Pretax Income | -271.37M |
| Net Income | -271.60M |
| EBITDA | -279.37M |
| EBIT | -281.82M |
| Earnings Per Share (EPS) | -3.51 |
Balance Sheet
EyePoint Pharmaceuticals, Inc. holds 222.55M in cash and equivalents against 20.23M in total debt, resulting in a net debt position of -77.71M. Total book value stands at -1.19B, with working capital of 212.04M providing operational flexibility.
| Cash & Cash Equivalents | 222.55M |
| Total Debt | 20.23M |
| Net Debt | -77.71M |
| Equity (Book Value) | -1.19B |
| Book Value Per Share | -15.39 |
| Working Capital | 212.04M |
Cash Flow
EyePoint Pharmaceuticals, Inc. produced -267.54M in operating cash flow over the past twelve months. After subtracting -4.00M in capital expenditures, free cash flow totaled -271.54M - equivalent to -3.51 per share.
| Operating Cash Flow | -267.54M |
| Capital Expenditures | -4.00M |
| Free Cash Flow | -271.54M |
| FCF Per Share | -3.51 |
Margins
EyePoint Pharmaceuticals, Inc. operates with a gross margin of 76.51, reflecting its pricing power and cost economics. The operating margin of -3,700.89 and net profit margin of -3,566.63 provide insight into operational efficiency.
| Gross Margin | 76.51 |
| Operating Margin | -3,700.89 |
| Pretax Margin | -3,563.62 |
| Profit Margin | -3,566.63 |
| EBITDA Margin | -3,668.75 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -17.26 |
| FCF Yield | -26.46 |
Stock Splits
EyePoint Pharmaceuticals, Inc.'s most recent stock split took place on December 9, 2020 with a 10:1 split ratio.
| Last Split Date | 12/9/2020 |
| Split Ratio | 10:1 |
Scores
EyePoint Pharmaceuticals, Inc. posts an Altman Z-Score of 2.25, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.25 |